Jul 1 |
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
|
Jun 18 |
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
|
Jun 14 |
Candel Therapeutics' (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
|
Jun 14 |
7 A-Rated Biotech Stocks Worth Betting on in June
|
Jun 11 |
Candel Therapeutics to join Russell 3000 Index
|
Jun 11 |
Candel Therapeutics to Join Russell 3000® Index
|
Jun 3 |
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
|
May 30 |
Candel gains FDA orphan status for brain tumor candidate
|
May 30 |
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
|
May 28 |
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
|